Shop - Cagrilintide 10mg Vial for Obesity & No Mass Loss

Description

Cagrilintide is an investigational long-acting amylin analogue developed for the treatment of obesity and overweight in individuals with or without type 2 diabetes. It mimics the physiological effects of endogenous amylin, a hormone co-secreted with insulin, to regulate appetite and food intake. Cagrilintide works by delaying gastric emptying and increasing satiety signals in the brain, leading to reduced caloric intake and body weight. It is being evaluated as a once-weekly subcutaneous injection, often in combination with GLP-1 receptor agonists such as semaglutide, and other GLPs to enhance weight loss outcomes.

Research Applications

Cagrilintide is being studied for its potential roles in:

• Appetite suppression and enhanced satiety for significant weight loss
• Improved glycemic control in individuals with obesity or type 2 diabetes
• Combination therapy for enhanced weight loss when paired with GLP-1 receptor agonists
• Reduction of cardiometabolic risk factors associated with obesity

Cagrilintide Structure and Mechanism

In clinical trials, Cagrilintide has demonstrated robust weight loss effects, with studies indicating it can achieve even greater reductions when combined with GLP-1 receptor agonists.

Legal Disclaimer

This product is sold as a pure research compound and is not intended for human consumption or use as a dietary supplement, drug, or treatment. It is provided solely for laboratory research purposes and must not be used for diagnostic or therapeutic purposes, in food, cosmetics, or any medical applications.

The statements on this website have not been evaluated by the U.S. Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease or medical condition. All products are for research and development use only.